TimesSquare Capital Management LLC Has $25.64 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

TimesSquare Capital Management LLC lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 10.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,183 shares of the company's stock after selling 16,685 shares during the quarter. TimesSquare Capital Management LLC owned approximately 0.49% of Krystal Biotech worth $25,636,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of KRYS. Norges Bank bought a new position in shares of Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. raised its stake in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after acquiring an additional 141,400 shares during the period. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 50,249.4% during the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock valued at $21,878,000 after purchasing an additional 121,101 shares during the last quarter. Raymond James Financial Inc. bought a new position in Krystal Biotech during the fourth quarter worth $15,989,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 6,927 shares of the business's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $150.27, for a total transaction of $1,040,920.29. Following the sale, the insider owned 1,525,929 shares in the company, valued at $229,301,350.83. The trade was a 0.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 13,927 shares of company stock valued at $2,092,852. 13.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have commented on KRYS shares. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Guggenheim dropped their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and set a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a report on Wednesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research report on Tuesday, June 24th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Krystal Biotech currently has an average rating of "Buy" and an average target price of $213.75.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $2.24 during trading on Monday, reaching $150.41. 265,292 shares of the company's stock were exchanged, compared to its average volume of 320,772. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34. The company has a market cap of $4.35 billion, a P/E ratio of 36.16 and a beta of 0.67. The firm's 50-day moving average price is $135.82 and its 200 day moving average price is $156.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).